DNDN un titolo per chi ha le coronarie forti
- Creatore Discussione osinod
- Data di Inizio
osinod
Banned
Institutional Holders SummaryDendreon Corp DNDN.O (NASDAQ)
Sector: Healthcare Industry: Biotechnology & Drugs View DNDN.O on other exchanges
As of 11:00 PM EST
$7.70USD Price Change
0.00 Percent Change
0.00%
% Shares Owned: 38.15% # New Positions: 35
# of Holders: 107 # Closed Positions: 19
Total Shares Held: 31,859,539 # Increased Positions: 30
3 Mo. Net Change: 4,755,586 # Reduced Positions: 21
Price Range Quarter: 7.05 - 15.03
Sector: Healthcare Industry: Biotechnology & Drugs View DNDN.O on other exchanges
As of 11:00 PM EST
$7.70USD Price Change
0.00 Percent Change
0.00%
% Shares Owned: 38.15% # New Positions: 35
# of Holders: 107 # Closed Positions: 19
Total Shares Held: 31,859,539 # Increased Positions: 30
3 Mo. Net Change: 4,755,586 # Reduced Positions: 21
Price Range Quarter: 7.05 - 15.03
osinod
Banned
Jun. 15, 2007 40,847,280
May 15, 2007 41,662,926
Apr. 13, 2007 33,901,959
Mar. 15, 2007 26,419,737
Feb. 15, 2007 20,306,278
Jan. 12, 2007 16,799,777
Dec. 15, 2006 13,055,168
Nov. 15, 2006 12,425,374
Oct. 13, 2006 12,323,167
Sep. 15, 2006 12,565,560
Aug. 15, 2006 12,873,103
Jul. 14, 2006 12,427,592
questo l' andamento dello short totale , certo si è passati dai circa 10 milioni agli attuali 40 milioni segno che molti credono in una caduta del titolo
pero' potrebbe essere vero anche il contrario
ora queste persone devono coprire lo short
May 15, 2007 41,662,926
Apr. 13, 2007 33,901,959
Mar. 15, 2007 26,419,737
Feb. 15, 2007 20,306,278
Jan. 12, 2007 16,799,777
Dec. 15, 2006 13,055,168
Nov. 15, 2006 12,425,374
Oct. 13, 2006 12,323,167
Sep. 15, 2006 12,565,560
Aug. 15, 2006 12,873,103
Jul. 14, 2006 12,427,592
questo l' andamento dello short totale , certo si è passati dai circa 10 milioni agli attuali 40 milioni segno che molti credono in una caduta del titolo
pero' potrebbe essere vero anche il contrario
ora queste persone devono coprire lo short
osinod
Banned
news di oggi fonte yahoo :
Tuesday, July 03, 2007
Dendreon Deservingly Jumps on New Cancer Vaccine Report
by Hisham S. Ayoub, DMD
BioHealth Investor
A new study published in the peer reviewed publication Clinical Cancer Research found that human trials of the new class of cancer vaccines, which includes Dendreon's (DNDN) Provenge for prostate cancer, have been aiming for a primary endpoint that is irrelevant.
Typically, the success of cancer treatments in clinical trials is measured by the reduction in the size of tumors. This was apparently the reason why the FDA refused to give Provenge final approval, citing that the average size in prostate tumors did not significantly shrink.
The new study however, points out that most cancer vaccine trials have increased the survival rate of patients, regardless of the change in size of tumors during the study period. Cancer vaccines need more time to work in order to induce changes in the immune system of patients to fight off the cancer.
As expected, shares of Dendreon jumped more than 6% on Tuesday on the study findings, and deservingly so.
Imagine calling a clinical study a failure because the tumor size did not significantly decrease, yet the average survival rate of patients increased!
Is it not the survival of patients the real aim of medical treatment?
Provenge deserves a second hard look by the FDA, and Dendreon stock still has a lot of room to the upside; deservingly so.
RELATED READING:
- Options Expiration Weighing on Dendreon
- Cell Genesys Should Not Trade With Dendreon!
- Dendreon Taps Financing Sooner Than Expected
- Analysts Continue to Dump on Dendreon
Tuesday, July 03, 2007
Dendreon Deservingly Jumps on New Cancer Vaccine Report
by Hisham S. Ayoub, DMD
BioHealth Investor
A new study published in the peer reviewed publication Clinical Cancer Research found that human trials of the new class of cancer vaccines, which includes Dendreon's (DNDN) Provenge for prostate cancer, have been aiming for a primary endpoint that is irrelevant.
Typically, the success of cancer treatments in clinical trials is measured by the reduction in the size of tumors. This was apparently the reason why the FDA refused to give Provenge final approval, citing that the average size in prostate tumors did not significantly shrink.
The new study however, points out that most cancer vaccine trials have increased the survival rate of patients, regardless of the change in size of tumors during the study period. Cancer vaccines need more time to work in order to induce changes in the immune system of patients to fight off the cancer.
As expected, shares of Dendreon jumped more than 6% on Tuesday on the study findings, and deservingly so.
Imagine calling a clinical study a failure because the tumor size did not significantly decrease, yet the average survival rate of patients increased!
Is it not the survival of patients the real aim of medical treatment?
Provenge deserves a second hard look by the FDA, and Dendreon stock still has a lot of room to the upside; deservingly so.
RELATED READING:
- Options Expiration Weighing on Dendreon
- Cell Genesys Should Not Trade With Dendreon!
- Dendreon Taps Financing Sooner Than Expected
- Analysts Continue to Dump on Dendreon
osinod
Banned
news di oggi sempre yahoo , ma questa volta di segno contrario cramer e molte altre case di investimento sono molto negative su dndn:
Dendreon Gets Divorced From Any Sane Reality
By Adam Feuerstein
Senior Writer
7/5/2007 6:50 AM EDT
Click here for more stories by Adam Feuerstein
TD AMERITRADE
E*TRADE FINANCIAL
Zecco.com
Fidelity Investments
Diora Financial
Fisher Investments
As if we needed it, we now have even more evidence that Dendreon (DNDN - Cramer's Take - Stockpickr - Rating) is in no way a fundamental stock story tied to its Provenge prostate cancer vaccine.
What the stock has become, instead, is the momentum trading vehicle of 2007. A stock that will be pumped and dumped based on the flimsiest of rumors and lowest-common-denominator reporting.
The latest antics occurred Tuesday when CNBC reporter Mike Huckman went on air with a promise of big news on Dendreon -- the publication of a new paper in the Journal of Clinical Cancer Research, which he claimed was "taking a second look" at Provenge, concluding that cancer vaccines might be helping patients live longer.
For dramatic effect, Huckman waved a copy of the report in the air like he was holding the Holy Grail.
Well, what the report actually says -- if you take the time to read it -- is that when it comes to cancer vaccines (Provenge and others), using traditional clinical endpoints for cancer trials like tumor shrinkage might not be the best way to assess efficacy. Instead, it might be better to judge cancer vaccines based on their ability to boost survival of patients.
Duh! What's new here? This is precisely the debate about Provenge rehashed. The Food and Drug Administration has already looked at the Provenge survival data and found it lacking. That's why the drug wasn't approved, and why the FDA wants more survival data from an ongoing study
Dendreon Gets Divorced From Any Sane Reality
By Adam Feuerstein
Senior Writer
7/5/2007 6:50 AM EDT
Click here for more stories by Adam Feuerstein
TD AMERITRADE
E*TRADE FINANCIAL
Zecco.com
Fidelity Investments
Diora Financial
Fisher Investments
As if we needed it, we now have even more evidence that Dendreon (DNDN - Cramer's Take - Stockpickr - Rating) is in no way a fundamental stock story tied to its Provenge prostate cancer vaccine.
What the stock has become, instead, is the momentum trading vehicle of 2007. A stock that will be pumped and dumped based on the flimsiest of rumors and lowest-common-denominator reporting.
The latest antics occurred Tuesday when CNBC reporter Mike Huckman went on air with a promise of big news on Dendreon -- the publication of a new paper in the Journal of Clinical Cancer Research, which he claimed was "taking a second look" at Provenge, concluding that cancer vaccines might be helping patients live longer.
For dramatic effect, Huckman waved a copy of the report in the air like he was holding the Holy Grail.
Well, what the report actually says -- if you take the time to read it -- is that when it comes to cancer vaccines (Provenge and others), using traditional clinical endpoints for cancer trials like tumor shrinkage might not be the best way to assess efficacy. Instead, it might be better to judge cancer vaccines based on their ability to boost survival of patients.
Duh! What's new here? This is precisely the debate about Provenge rehashed. The Food and Drug Administration has already looked at the Provenge survival data and found it lacking. That's why the drug wasn't approved, and why the FDA wants more survival data from an ongoing study
osinod
Banned
il blog tradotto delle biotech :
http://translate.google.com/transla...umps-on-new.html&langpair=en|it&hl=it&ie=UTF8
http://translate.google.com/transla...umps-on-new.html&langpair=en|it&hl=it&ie=UTF8
osinod
Banned
premarket last 7,8$ :
Dendreon Corporation
Pre-Market Quotes | Pre-Market Charts | After Hours Quotes | After Hours Charts Jul. 3, 2007 Market Close: $ 7.70
Pre-Market Trade Reporting
Pre-Market
Last: $ 7.80 Pre-Market
High: $ 7.87
Pre-Market
Volume: 122,744 Pre-Market
Low: $ 7.60
Pre-Market
Time (ET) Pre-Market
Price Pre-Market
Share Volume
08:21 $ 7.80 100
08:21 $ 7.80 100
08:21 $ 7.80 100
08:21 $ 7.80 700
08:21 $ 7.79 250
08:20 $ 7.77 450
08:20 $ 7.77 550
08:20 $ 7.77 150
08:20 $ 7.80 200
08:20 $ 7.80 100
08:20 $ 7.80 200
08:20 $ 7.80 300
08:20 $ 7.80 300
08:20 $ 7.80 600
08:20 $ 7.80 100
08:20 $ 7.76 100
08:20 $ 7.80 200
08:20 $ 7.80 300
08:19 $ 7.78 300
08:18 $ 7.83 100
08:18 $ 7.83 100
08:18 $ 7.83 300
08:18 $ 7.83 200
08:18 $ 7.82 100
08:18 $ 7.82 100
08:18 $ 7.82 400
08:18 $ 7.82 100
08:18 $ 7.81 2,000
08:18 $ 7.81 195
08:18 $ 7.81 100
08:18 $ 7.81 500
08:18 $ 7.80 500
08:18 $ 7.80 200
08:18 $ 7.81 500
08:17 $ 7.82 900
08:17 $ 7.83 300
08:17 $ 7.83 175
08:17 $ 7.83 300
08:17 $ 7.83 700
08:17 $ 7.83 2,525
08:17 $ 7.83 245
08:17 $ 7.83 300
08:17 $ 7.83 1,455
08:17 $ 7.83 300
08:17 $ 7.83 645
08:17 $ 7.85 100
08:17 $ 7.85 250
08:17 $ 7.85 250
08:16 $ 7.81 100
08:16 $ 7.81 1,000
1 2 3 4 5 Next
Dendreon Corporation
Pre-Market Quotes | Pre-Market Charts | After Hours Quotes | After Hours Charts Jul. 3, 2007 Market Close: $ 7.70
Pre-Market Trade Reporting
Pre-Market
Last: $ 7.80 Pre-Market
High: $ 7.87
Pre-Market
Volume: 122,744 Pre-Market
Low: $ 7.60
Pre-Market
Time (ET) Pre-Market
Price Pre-Market
Share Volume
08:21 $ 7.80 100
08:21 $ 7.80 100
08:21 $ 7.80 100
08:21 $ 7.80 700
08:21 $ 7.79 250
08:20 $ 7.77 450
08:20 $ 7.77 550
08:20 $ 7.77 150
08:20 $ 7.80 200
08:20 $ 7.80 100
08:20 $ 7.80 200
08:20 $ 7.80 300
08:20 $ 7.80 300
08:20 $ 7.80 600
08:20 $ 7.80 100
08:20 $ 7.76 100
08:20 $ 7.80 200
08:20 $ 7.80 300
08:19 $ 7.78 300
08:18 $ 7.83 100
08:18 $ 7.83 100
08:18 $ 7.83 300
08:18 $ 7.83 200
08:18 $ 7.82 100
08:18 $ 7.82 100
08:18 $ 7.82 400
08:18 $ 7.82 100
08:18 $ 7.81 2,000
08:18 $ 7.81 195
08:18 $ 7.81 100
08:18 $ 7.81 500
08:18 $ 7.80 500
08:18 $ 7.80 200
08:18 $ 7.81 500
08:17 $ 7.82 900
08:17 $ 7.83 300
08:17 $ 7.83 175
08:17 $ 7.83 300
08:17 $ 7.83 700
08:17 $ 7.83 2,525
08:17 $ 7.83 245
08:17 $ 7.83 300
08:17 $ 7.83 1,455
08:17 $ 7.83 300
08:17 $ 7.83 645
08:17 $ 7.85 100
08:17 $ 7.85 250
08:17 $ 7.85 250
08:16 $ 7.81 100
08:16 $ 7.81 1,000
1 2 3 4 5 Next
Similar threads
